It showed that significant HBsAg decreases were observed in lower baseline HBsAg group (Z=-2.277, P=0.023) (Figure 2B), HBeAg-seronegative group (Z=-2.200, P=0.028) (Figure 2C), non-irAEs occurrence group (Z=-2.007, P=0.045) (Figure 2D) and liver cancer group (Z=-1.987, P=0.047) (Figure 2E), while no difference of HBsAg changes was found when patients were divided into groups according to the types of NAs, baseline HBV-DNA levels, liver cirrhosis, prior use of antiviral therapy, the cycles of PD-1 inhibitors, and the types of PD-1 inhibitors (Supplementary Figure 1). This evidence concerns the gene PDCD1 and liver cancer.